Chromium picolinate and chromium histidinate protects against renal dysfunction by modulation of NF-κB pathway in high-fat diet fed and Streptozotocin-induced diabetic rats by Selcuk, Mustafa Yavuz et al.
RESEARCH Open Access
Chromium picolinate and chromium histidinate
protects against renal dysfunction by modulation
of NF-B pathway in high-fat diet fed and
Streptozotocin-induced diabetic rats
Mustafa Yavuz Selcuk
1, Bilge Aygen
1, Ayhan Dogukan
1, Zeynep Tuzcu
2, Fatih Akdemir
3, James R Komorowski
4,
Mustafa Atalay
5 and Kazim Sahin
3,6*
Abstract
Background: Diabetic nephropathy is one of major complications of diabetes mellitus. Although chromium is an
essential element for carbohydrate and lipid metabolism, its effects on diabetic nephropathy are not well
understood. The present study was conducted to investigate the effects of chromium picolinate (CrPic) and
chromium histidinate (CrHis) on nuclear factor-kappa B (NF-B) and nuclear factor-E2-related factor-2 (Nrf2)
pathway in the rat kidney.
Methods: Male Wistar rats were divided into six groups. Group I received a standard diet (8% fat) and served as a
control; Group II was fed with a standard diet and received CrPic; Group III was fed with a standard diet and
received CrHis; Group IV received a high fat diet (HFD, 40% fat) for 2 weeks and then were injected with
streptozotocin (STZ) (HFD/STZ); Group V was treated as group IV (HFD/STZ) but supplemented with CrPic for 12
weeks. Group VI was treated as group IV (HFD/STZ) but supplemented with CrHis.
Results: The increased NF-b p65 in the HFD/STZ group was inhibited by CrPic and CrHis supplementation (P <
0.05). In STZ-treated rats, a significant decrease in levels of nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, alpha (IBa) was found in kidney tissues when compared to control rats (P < 0.05). A significant
increase in the levels of IBa was observed in CrPic- and CrHis-treated rats when compared with STZ-treated rats.
Renal Nrf2 levels were significantly decreased in diabetic rats compared with the control rats. There was a higher
tendency for increase of kidney Nrf2 level and decrease in kidney NFBp65 levels and 4- hydroxyl nonenal (4-HNE)
protein adducts (P < 0.05) in diabetic rats.
Conclusion: Our result show that in kidney tissue CrHis/CrPic increases Nrf2 level, parallelly decreases NF-B and
partially restores IBa levels in HFD/STZ group, suggesting that CrPic and CrHis may play a role in antioxidant
defense system via the Nrf2 pathway by reducing inflammation through NF-b p65 inhibition. Moreover, a greater
reduction in NF-B expression and greater increases in expressions of IBa and Nrf2 in diabetic rats supplemented
with CrHis than rats supplemented with CrPic suggest that CrHis has more favorable effects than CrPic.
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Nutrition plays an important role in the development
and also in the prevention of cancer, cardiovascular dis-
eases, and diabetes. A high-fat diet can induce obesity
and metabolic disorders, insulin resistance, dyslipidemia,
and hypertension in rodents and in humans [1-3]. High-
fat diets (HFD) may induce changes not only in energy
metabolism but also in liver, kidney and brain function.
Diabetes mellitus, a well-known endocrine metabolic
disorder, is disease characterized by high levels of blood
glucose and multiple tissue complications, resulting in
nephropathy, neuropathy and retinopathy [4]. Oxidative
stress and disrupted redox regulation play an important
role in the pathogenesis of diabetes and one of the
major complications is renal and, in addition to cerebro-
vascular and ocular complications [5-8]. The production
of tumor necrosis factor (TNF)-a and expression of
nuclear transcription factor kappa B (NFB) can be sti-
mulated by over production of reactive oxygen species
(ROS) [9]. Inflammatory proteins may also participate in
the pathogenesis of insulin resistance and its complica-
tions [10] and therefore, mechanisms by which insulin
resistance occurs are explained by excessive activities in
the NFB pathway and of inflammatory cytokines
[11-13]. Activated the inhibitor of NF-B kinase (IKK),
caused by cytokines, hyperglycemia and elevated free
fatty acids (FFAs), results in the nuclear factor of kappa
light polypeptide gene enhancer in B-cells inhibitor,
alpha (IBa) polyubiquitination and proteosomal degra-
dation, and subsequent release of NFB, especially p50/
p65, to the nucleus where it can bind to the response
element of target genes involved in the inflammatory
response [14-16]. In return sustained activation of NFB
caused by overexpression of IKK in the liver leads to
insulin resistance [14].
Some strategies to alleviate insulin resistance by nutri-
tional supplements appear to improve insulin sensitivity
in many individuals and improve glycemic control in
diabetics [17]. Chromium (Cr) is required for normal
carbohydrate, protein and lipid metabolism and its defi-
ciency has been implicated as one of the causes of dia-
betes mellitus [18-20]. Supplementations of available Cr
chelates with picolinic acid (CrPic) [21,22] and histidi-
nate (CrHis) [23] have been shown to exert beneficial
effects for the management of type-2 diabetes, as
reflected by a decline in insulin response.
Several studies reported that CrPic and CrHis may
enhance insulin receptor binding [24], increase the
number of insulin receptors [25] and insulin receptor
phosphorylation [26], resulting in the reduction of insu-
lin resistance in peripheral tissues [27]. One of the intra-
cellular proteins influencing the insulin receptor is the
oligopeptide low molecular weight chromium binding
substance (LMWCr, apochromodulin) which is widely
distributed in the liver, kidneys, spleen, intestine, testi-
cles and brain [28,29]. This peptide, which activates tyr-
osine kinase, depends on Cr concentration and
promotes insulin receptor activity.
Although numerous studies have been published
examining the health aspects of chromium on humans
and animals, there have been scarce studies to investi-
gate the effects of CrHis on the IB/NF-B pathway or
Nrf2 response in diabetic nephropathy. Therefore, the
current study was performed to investigate the effect of
CrHis/CrPic supplementation on changes in IB/NF-B
pathway and Nrf2 levels in the diabetic nephropathy.
Methods
Animals and diets
Male Wistar rats (n = 90, 8 wk-old) weighing 200-250
gr were purchased from Firat University Laboratory Ani-
mal Research Center (Elazig, Turkey). These animals
were reared at the temperature of 22 ± 2°C, humidity of
55 ± 5%, and with a 12/12 h light/dark cycle. The
experiment was conducted under the protocol approved
by the Ethical Committee of Firat University. All proce-
dures involving rats were conducted in strict compliance
with relevant laws, the Animal Welfare Act, Public
Health Services Policy, and guidelines established by the
Institutional Animal Care and Use Committee of the
University. Rats consumed a standard diet and tap water
ad libitum. Blood samples were collected from the tail
vein of each rat for the measurement of biochemical
efficacy markers. Rats were randomly assigned to treat-
ment groups. The rats were fed with standard (control)
diet (8% fat) or high fat diet (HFD) containing 40% fat
Table 1 Composition of diets (g/kg diet) fed to rats
Ingredients Regular Diet High Fat Diet
Casein 200.0 200.0
Starch 615.0 145.0
Sucrose - 150.0
Corn oil 80.0 -
Beef tallow - 400.0
Cellulose 50.0 50.0
Vitamin-Mineral Premix* 50.0 50.0
DL-Methionine 3.0 3.0
Choline cloride 2.0 2.0
Chromium, mg/kg 0.066 0.097
*The vitamin-mineral premix provides the following (per kg): all-trans-retinyl
acetate, 1.8 mg; cholecalciferol, 0.025 mg; all-rac-a-tocopherol acetate, 12,5
mg; menadione (menadione sodium bisulfate), 1.1 mg; riboflavin, 4.4 mg;
thiamine (thiamine mononitrate), 1.1 mg; vitamin B-6, 2.2 mg; niacin, 35 mg;
Ca-pantothenate, 10 mg; vitamin B-12, 0.02 mg; folic acid, 0.55 mg; d-biotin,
0.1 mg. manganese (from manganese oxide), 40 mg; iron (from iron sulfate),
12.5 mg; zinc (from zinc oxide), 25 mg; copper (from copper sulfate), 3.5 mg;
iodine (from potassium iodide), 0.3 mg; selenium (from sodium selenite), 0.15
mg; choline chloride, 175 mg
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CrPic and CrHis (Nutrition 21, Inc. NY, USA).
Ingredients and chemical composition of the basal
(control) diet are shown in Table 1. The diets were
stored at 4°C cold chamber. Animals were fed either
with a normal diet consisting of 8% fat or a HFD con-
sisting of 40% fat. CrPic and CrHis (Nutrition 21, Inc.,
Purchase, NY, USA) were dissolved in water and admi-
nistered at a concentration of 22 μg CrPic and CrHis
were delivered via drinking water for 12 weeks (provid-
ing 8 mcg Cr/day), which is an equivalent dose of 560
μg Cr for a 70 kg adult human.
Experimental design and induction of type II diabetes
A rat model of type-2 diabetes which was created by
feeding with a HFD and STZ treatment, developed by
Reed et al. [30]. This model provides a novel animal
model for type-2 diabetes that is applicable to the
human syndrome making it suitable for testing antidia-
betic compounds. In using such a model, the increased
hyperglycemia after STZ injection in high-fat fed rats
was not due to a greater decline in B-cell function
[30,31]. The animals of the present work were divided
into 6 groups as: Group I: rats were fed with a standard
diet (8% fat); Group II: rats were fed with standard diet
and received CrPic; Group III: rats were fed with stan-
dard diet (8% fat) and received CrHis; Group IV (HFD/
STZ) (rats were fed with a HFD (40% fat) for 2 weeks
and then injected with STZ (40 mg/kg i.p.); Group V
(HFD/STZ + CrPic) (rats were fed with a high-fat diet
(40% fat) for 2 weeks and then injected with STZ (40
mg/kg i.p.) and received CrPic; Group VI (HFD/STZ +
CrHis) (rats were fed a high-fat diet (40% fat) for 2
weeks and then injected with STZ (40 mg/kg i.p.) and
received CrHis. CrHis and CrPic were included into
water and administered at a concentration of 22 μg
CrPic and CrHis 12 weeks.
Before STZ injection, glucose concentrations of rats
were measured and compared to controls. After STZ
injection, animals exhibiting fasting glucose levels > 140
mg/dl were considered as STZ diabetic; resembling
type-2 diabetes in human. CrPic and CrHis were then
administered.
Western blot analyses
In all groups, rats were sacrificed by cervical dislocations
and kidneys were promptly removed. Protein extraction
was performed as follows. The sample was homogenized
in ice-cold in 1 ml of hypotonic buffer A [10 mM
HEPES (pH 7.8), 10 mM KCl, 2 mM MgCl2, 1 mM
DTT, 0.1 mM EDTA, 0.1 mM phenylmethylsulfonyl-
fluoride (PMSF)]. A solution of 80 μlo f1 0 %N o n i d e t
P-40 (NP-40) was added to the homogenates, and the
mixture was centrifuged for 2 min at 14,000 g. The
supernatant was collected as a cytosolic fraction for the
assays of IBa and 4- hydroxyl nonenal (4-HNE)
adducts. The precipitated nuclei were washed once with
500 μl of buffer A plus 40 μl of 10% NP-40, centrifuged,
resuspended in 200 μl of buffer C [50 mM HEPES (pH
7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM
DTT, 0.1 mM PMSF, 20% glycerol] and centrifuged for
5 min at 14,800 g. The supernatant containing nuclear
proteins was collected for Nrf2 and NFB p65 [32].
Concentration of the protein was determined according
to the procedure described by Lowry et al. [33] using a
protein assay kit supplied by Sigma, St. Louis, MO,
USA. Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis sample buffer containing 2% b-mercaptoetha-
nol was added to the supernatant. Equal amounts of
protein (50 μg) were electrophoresed and subsequently
transferred to nitrocellulose membranes (Schleicher and
Schuell Inc., Keene, NH, USA). Nitrocellulose blots were
washed twice for 5 min each in PBS and blocked with
1% bovine serum albumin in PBS in room temperature
for 1 h prior to application of the primary antibody. The
antibody against Nrf2 and 4-HNE adducts were the pur-
chased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA) and from 4 Alpha Diagnostics (San
Antonio, TX) respetively. Antibody against IBa and
NF-B p65 were purchased from Abcam (Cambridge,
UK). Primary antibody was diluted (1:1000) in the same
buffer containing 0.05% Tween-20. The nitrocellulose
membrane was incubated overnight at 4°C with protein
antibody. The blots were washed and incubated with
horseradish peroxidase-conjugated goat anti-mouse IgG
(Abcam, Cambridge, UK). Specific binding was detected
using diaminobenzidine and H2O2 as substrates. Protein
loading was controlled using a monoclonal mouse anti-
body against b-actin antibody (A5316; Sigma). Blots
were performed at least three times to confirm the data
reproducibility. Bands were analyzed densitometrically
using an image analysis system (Image J; National Insti-
tute of Health, Bethesda, USA).
Statistical analysis
Sample size was calculated based on a power of 85% and
a P value of 0.05. Given that assumption, a sample size
of 10 rats per treatment was calculated. The data were
analyzed using the General Linear Model (GLM) proce-
dure of SAS software [34]. Least square treatments were
compared if a significant F statistic (5% level of P) was
detected by analysis of variance. Treatments were also
compared using student’s unpaired t test for comparison
of individual treatment. P < 0.05 was considered to be
statistically significant. Between group differences in
latencies were analyzed by the analysis of variance for
repeated measurements (ANOVAR) followed by Fisher’s
post hoc test for all groups.
Selcuk et al. Nutrition & Metabolism 2012, 9:30
http://www.nutritionandmetabolism.com/content/9/1/30
Page 3 of 7Results
Figure 1 shows the effects of CrPic and CrHis on NF-
b,I Ba, Nrf2 levels and 4-HNE protein adducts of kid-
ney in rats. In this study (Figure 1A), the kidney NF-b
p65 subunit level increased significantly in STZ and
HFD groups. After oral administration of CrPic and
CrHis, kidney NF-B level was not altered in rats fed a
regular diet, but significantly decreased in diabetic rats.
When Cr was supplemented as CrHis, compared to
CrPic, there was a greater decrease (P < 0.05) in kidney
NF-B level in diabetic rats. Renal IBa level assessed
by Western blotting and were significantly decreased in
diabetic rats compared with those in control rats (P <
0.05), where as CrPic- and CrHis treatment significantly
offset these increases in diabetic rats (P <0 . 0 1 )( F i g u r e
1B). In diabetic animals the level of IBa was signifi-
cantly increased by CrHis as compared to the similarly
treated CrPic groups. The protein levels of Nrf2 in the
renal tissues were also determined by Western blot ana-
lysis (Figure 1C). Based on the band densities, renal
Nrf2 level was significantly decreased in diabetic rats
compared with the control rats. However, these
decreases were partially compensated by the supple-
ments of CrPic and CrHis. Compared to CrPic, CrHis is
more effective in increasing these proteins. When Cr
was supplemented in CrHis form, compared to its CrPic
Figure 1 Western blot analysis of NF-Bp65, IB, Nrf2 and 4-HNE protein adducts in kidney homogenates of controls and chromium-
treated rats. Densitometric analyses of these bands are represented as percent of control. Values are means ± standard error of the mean. Blots
were repeated at least 3 times (n = 3) and a representative blot is shown. Actin was included to ensure equal protein loading. Data points with
different superscripts are significantly different at the level of P < 0.05 by Fisher’s comparison test. Control: no treatment; CrPic: Fed with
standard diet and received CrPic; C + CrHis: fed with standard diet (8% fat) and received CrHis; HFD + STZ: received a HFD (40% fat) for 2 weeks
and then were injected with streptozotocin (STZ) on day 14 (STZ,40 mg/kg i.p); HFD + STZ + CrPic: Treated with HFD/STZ but supplemented
with CrPic. HFD + STZ + CrHis: Treated with HFD/STZ but supplemented CrHis. The mean bars with different letters differ (P < 0.05).
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Nrf2 level in diabetic rats. However, level of these pro-
teins in kidney was not affected by CrPic and CrHis
supplementation in control rats fed a normal diet. The
kidney 4-HNE protein adducts increased significantly in
STZ and HFD groups. After oral administration of
CrPic and CrHis, kidney 4-HNE protein adducts were
not altered in rats fed regular diet, but were significantly
decreased in diabetic rats (Figure 1D). Taken all
together, CrPic and CrHis effects were similar when rats
fed normal diet, but CrHis was superior to CrHis, as
reflected by a greater reduction in NF-B levels and 4-
HNE protein adducts and greater increases in the levels
of IBa and Nrf2 in diabetic rats.
Discussion
Chromium supplementation as chromium chloride
(CrCl3) [35,36], chromium niacinate (Cr-N), CrPic [37]
and CrHis [22] has been shown to inhibit the increase
in inflammatory markers and oxidative stress levels in
cultured monocytes exposed to high glucose levels.
However, no research was reported in the literature for
the effects of CrPic and CrHis supplementation on the
kidney levels of NFB, IBa, Nrf2 and 4-HNE protein
adducts in an animal model of diabetes. The results
of the present work showed that CrPic and CrHis
decreased NF-B level in kidney of the rats with HFD/
STZ-induced diabetes, indicating that CrPic and CrHis
decreases 4-HNE protein adducts via the Nrf2/ARE-
mediated pathway. In parallel with the results of the
present work, Kuhad et al. [38] reported that NFb p65
subunit was significantly elevated in the kidneys of dia-
betic animals. These results are consistent with previous
studies showing that CrPic supplementation improves
r e n a lf u n c t i o ni nS T Z - d i a b e t i cr a t s[ 3 9 , 4 0 ] .S i m i l a rt o
the results of the present work, other reports have
shown that diabetes causes alterations in the synthesis
or concentrations of cytokines [36,37,41]. Chen et al.
[42] showed that the levels of NF-B p65 in kidneys
were distinctly increased in lower dose STZ-induced
diabetic rat model fed with a high-fat diet. In addition,
Bi et al. [16] reported that insulin treatment inhibits
liver NF-B activity and inflammatory cytokine
responses involved in the amelioration of insulin resis-
tance in diabetic rats. Jain et al. [37] reported that Cr-N
supplementation lowered the blood levels of tumor
necrosis-a (TNF-a), Interleukin -6 (IL-6), c-reactive
protein (CRP) and cholesterol, In addition CrPic supple-
mentation caused a decrease in TNF-a, IL-6 and lipid
peroxidation in rats [37].
Nrf2 controls the antioxidant response element (ARE)-
dependent gene regulation in response to oxidative
stress and contributes to protection against to the disor-
ders related to oxidative stress [43,44]. In the present
work, Nrf2 levels in the HFD/STZ-induced kidney injury
group was lower than those of controls, whereas CrPic
and CrHis treatment induced level of Nrf2 and
enhanced nuclear translocation and subsequent ARE
binding (Figure 1C). This finding shows that CrHis and
C r P i cm a yb ei n v o l v e di ns t a b i lization and maintaining
levels of Nrf2. Palsamy and Subramanian [45] reported
that during hyperglycemia-mediated oxidative stress, the
expression of Nrf2 and its downregulatory enzymes like
heme oxygenase- 1 were significantly decreased in the
renal tissues of diabetic rats. CrHis was shown to
reverse the deficits associated with obesity via up regu-
lating the expression of Nrf2 and HO-1 in the rats fed
HFD [46]. However, there are no previous studies inves-
tigating the effects of Cr supplementation on the Nrf2
in diabetic nephropathy comparable with this study.
Oxidative stress associated with overproduction of
ROS plays an important role in the development of dia-
betic complications including diabetic nephropathy [47].
These modifications can cause some morphological and
functional disorders in the kidney of diabetic patients.
The reaction of ROS with membrane lipids causes the
formation of lipid peroxidation products including sev-
eral aldehydic compounds, one of which is highly toxic
and called as 4- HNE adducts. 4-HNE adducts, an indi-
cator of lipid peroxidation, in kidney of diabetic rats
were decreased when dietary CrHis or CrPic was sup-
plemented. CrHis supplementation did not alter these
parameters in non-diabetic rats. The current study
a p p e a r st ob et h ef i r s tt oe x a mine the specific associa-
tion between dietary CrPic/CrHis intake and 4-HNE in
diabetic rats. Significantly lower levels of 4- HNE adduct
were observed in diabetic animals receiving Cr supple-
mentation. These findings indicate significant positive
associations between Cr intake and 4- HNE adducts for
diabetic rats. These results confirm previous findings
that the level of HNE is altered in diabetes, resulting in
increased susceptibility of the tissues to injury [48].
CrHis [22,46] and CrPic [37], playing an important role
against insulin resistance, is postulated to augment anti-
oxidant defense system. Previous studies have also
demonstrated that CrCl3 supplementation inhibited the
increase in TNF-a and oxidative stress levels in cultured
monocytes exposed to high glucose levels [35,36]. Simi-
larly, Jain et al. [37] reported that CrPic supplementa-
tion showed a decrease in lipid peroxidation, TNF-a,
IL-6 in rats. Preuss et al. [39] also reported a decrease
in hepatic thiobarbituric acid-reactive substances
(TBARS) formation by supplementation of CrPic and Cr
nicotinate in rats.
Conclusion
The results of this study provide further evidence that
C r P i ca n dC r H i sm a yh a v eap r o t e c t i v er o l ea g a i n s t
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through an anti-inflammation effect by NF-Bi n h i b i -
tion. Moreover, a greater reduction in NF-B level and
greater increases in the levels of IBa and Nrf2 in dia-
betic rats supplemented with CrHis than rats supple-
mented with CrPic suggest that CrHis has more
favorable effects than CrPic.
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